The Kelly registry was launched in 2014 as a pilot project aiming to monitor and to evaluate data on the number of patients with non-small cell lung cancer (NSCLC) in the Czech Republic, and on their diagnostic records. The main objective of the project is to build up a database which would primarily serve as a source of anonymised information on this type of cancer in the Czech Republic.

The project was initiated at the Institute of Biostatistics and Analyses of the Masaryk University (IBA MU) and has continued at the Institute of Biostatistics and Analyses Ltd (IBA Ltd), a university company.

All newly diagnosed and microscopically verified cases of NSCLC are recorded into the registry. A number of histological parameters is recorded for each tumour, which will allow a detailed analysis to be performed later. In this way, the registry will provide a valuable feedback in terms of quality of individual laboratories.

The possibility of detailed monitoring of EGFR mutation testing results in the population of Czech NSCLC patients is a special feature of the Kelly registry. The registry has been designed as a tool which allows monitoring of the course and results of EGFR mutation testing as an important diagnostic marker in NSCLC, and a predictor for the use of targeted biological therapies, which are rather expensive, but very effective in appropriately selected patients. The registry makes it possible to analyse data on the numbers of performed molecular genetic examinations, and on the proportion of EGFR mutation-positive NSCLC according to individual centres and regions. The registry should also make it possible to trace back and to verify unclear findings.

Expert guarantor: Prof. Aleš Ryška, M.D., Ph.D.

Funding: Boehringer Ingelheim, Ltd.

Partners: 16 departments of pathology from across the Czech Republic (you can find more detailed information on the website of the Kelly project)